Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs

Description

The investigators are doing this study to find out whether lowering the dose of postoperative radiation therapy and targeting a smaller area of tissue for treatment is as effective as the standard dose and volume of radiation therapy to control soft tissue sarcoma after surgery. They also want to find out whether the study approach causes fewer and less severe long-term side effects than the standard approach.

Conditions

Soft Tissue Sarcoma

Talk to us

Study Overview

On this page

Study Details

Study overview

The investigators are doing this study to find out whether lowering the dose of postoperative radiation therapy and targeting a smaller area of tissue for treatment is as effective as the standard dose and volume of radiation therapy to control soft tissue sarcoma after surgery. They also want to find out whether the study approach causes fewer and less severe long-term side effects than the standard approach.

Reduction of Dose and Volume in Postoperative Radiation for Extremity Soft Tissue Sarcoma

Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs

Condition
Soft Tissue Sarcoma
Intervention / Treatment

-

Contacts and Locations

Basking Ridge

Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge, New Jersey, United States, 07920

Middletown

Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States, 07748

Montvale

Memorial Sloan Kettering Bergen (All protocol activities), Montvale, New Jersey, United States, 07645

Commack

Memorial Sloan Kettering Commack (All protocol activities), Commack, New York, United States, 11725

Harrison

Memorial Sloan Kettering Westchester (All protocol activities), Harrison, New York, United States, 10604

New York

Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065

Uniondale

Memorial Sloan Kettering Nassau (All protocol activities), Uniondale, New York, United States, 11553

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients must be diagnosed with a primary soft tissue sarcoma of the extremity, confirmed by MSKCC pathologic review
  • * Age at the time of enrollment of ≥18 years
  • * Patients must have undergone margin-negative oncologic resection of their primary tumor, as confirmed by MSKCC pathologic review
  • * Patients must be able to start radiation within 3 months from time of surgery
  • * Female patients of childbearing potential must have a negative serum pregnancy test within 14 days of radiation start (or if urine test, within 24 hours of radiation start)
  • * Sexually active patients of childbearing potential must agree to use effective contraception.
  • * The use of chemotherapy will not be dictated by this trial. Patients are allowed to receive chemotherapy at the discretion of the disease management team (as is standard practice to make individualized decisions for each patient regarding the use of chemotherapy).
  • * Patients with positive margins after surgical resection as indicated by MSKCC pathologic review
  • * Patients with diagnosis of superficial myxofibrosarcoma with indistinct/infiltrative borders on preoperative MRI16 (see Appendix Figure 1 for reference figure)
  • * Patients with multifocal disease in the extremity
  • * Patients who have received prior radiotherapy at or adjacent to the primary tumor bed
  • * Patients with a differentinvasive cancer requiring active treatment at the time of enrollment.
  • * Patients with any concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

Kaled Alektiar, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2025-02